Literature DB >> 11895927

Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function.

Robert L Giuntoli1, Jun Lu, Hiroya Kobayashi, Richard Kennedy, Esteban Celis.   

Abstract

The survival and proliferation of CTL during the effector phase of the immune response is critical for the elimination of infectious agents and tumor cells. We report here that in an in vitro model system, the expansion and cytolytic function of tumor-reactive human CTL can be enhanced by CD4(+) helper T lymphocytes through costimulatory signals that are mediated by cell surface molecules. The results presented here suggest that costimulatory receptors on CTL such as CD27, CD134 (4-1BB), and MHC class II are capable of directly interacting with the corresponding ligands on T-helper lymphocytes resulting in enhanced proliferation and survival of the CTL during the effector phase of antitumor immune responses. These findings underline the importance of antigen-specific helper T lymphocytes for the regulation and maintenance of CTL immunity, and have implications for the design of therapeutic vaccines for cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895927

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

Review 1.  T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.

Authors:  Melinda A Biernacki; Michelle Brault; Marie Bleakley
Journal:  Cancer J       Date:  2019 May/Jun       Impact factor: 3.360

2.  T helper lymphocytes rescue CTL from activation-induced cell death.

Authors:  Richard Kennedy; Esteban Celis
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

Review 3.  Vaccines targeting helper T cells for cancer immunotherapy.

Authors:  Marit Melssen; Craig L Slingluff
Journal:  Curr Opin Immunol       Date:  2017-07-26       Impact factor: 7.486

4.  Superior Immunologic and Therapeutic Efficacy of a Xenogeneic Genetic Cancer Vaccine Targeting Carcinoembryonic Human Antigen.

Authors:  Luigi Aurisicchio; Giuseppe Roscilli; Emanuele Marra; Laura Luberto; Rita Mancini; Nicola La Monica; Gennaro Ciliberto
Journal:  Hum Gene Ther       Date:  2015-06       Impact factor: 5.695

5.  Selective addition of CXCR3(+) CCR4(-) CD4(+) Th1 cells enhances generation of cytotoxic T cells by dendritic cells in vitro.

Authors:  Sung Hee Yoon; Sun Ok Yun; Jung Yong Park; Hee Yeun Won; Eun Kyung Kim; Hyun Jung Sohn; Hyun Il Cho; Tai Gyu Kim
Journal:  Exp Mol Med       Date:  2009-03-31       Impact factor: 8.718

6.  Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries.

Authors:  Wolfram Osen; Sabine Soltek; Mingxia Song; Barbara Leuchs; Julia Steitz; Thomas Tüting; Stefan B Eichmüller; Xuan-Duc Nguyen; Dirk Schadendorf; Annette Paschen
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

7.  In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells.

Authors:  Deepak Assudani; Hyun-Il Cho; Nicholas DeVito; Norma Bradley; Esteban Celis
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

8.  Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs.

Authors:  Shunroh Ohtsukasa; Satoshi Okabe; Hironori Yamashita; Takehisa Iwai; Kenichi Sugihara
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-15       Impact factor: 4.553

Review 9.  Peptide epitope identification for tumor-reactive CD4 T cells.

Authors:  Hiroya Kobayashi; Esteban Celis
Journal:  Curr Opin Immunol       Date:  2008-05-20       Impact factor: 7.486

10.  Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.

Authors:  Kyong Hwa Park; Ekram Gad; Vivian Goodell; Yushe Dang; Thayer Wild; Doreen Higgins; Patty Fintak; Jennifer Childs; Corazon Dela Rosa; Mary L Disis
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.